| Wissenschaftl. Titel | A Phase II/III, prospective, multi-Center, randomized, 4-Week, double-blind, placebo-controlled study, designed to determine the safety, tolerability, EEG effects and efficacy of oral doses of 30 mg BID oF Evenamide (NW-3509) in patients with chronic schziophrenia who are symptomatic on their current second-generation antipsychotic (ARIPIPRAZOLE, CLOZAPINE, QUETIAPINE, OLANZAPINE, PALIPERIDONE OR RISPERIDONE) medication |
| Erkrankung |
Psyche:
Schizophrenie
|
| Prüfzentren |
Psychiatrie, Psychosomatik und Psychotherapie
(Aktiv) Prof. Dr. med. Andreas Reif Tel: 069 / 6301 Fax: 069 / 5222 andreas.reif@unimedizin-ffm.de |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 19.01.2023 Nicole Wamser
geändert 30.06.2023 Admin02